Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia

References

• Wong TY, Ferreira A, Hughes R, et al. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol. 2014;157:9–25. doi:10.1016/j.ajo.2013.08.010.
   PubMed Web of Science ®Google Scholar
• Neelam K, Cheung CM, Ohno-Matsui K, et al. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res. 2012;31:495–525 doi:10.1016/j.preteyeres.2012.04.001.
   PubMed Web of Science ®Google Scholar
• Attebo K, Ivers RQ, Mitchell P. Refractive errors in an older population: the Blue Mountains Eye Study. Ophthalmology. 1999;106:1066–1072. doi:10.1016/S0161-6420(99)90251-8.
   PubMed Web of Science ®Google Scholar
• Lin LL, Shih YF, Hsiao CK, et al. Prevalence of myopia in Taiwanese schoolchildren: 1983 to 2000. Ann Acad Med Singapore. 2004;33:27–33.
   PubMed Web of Science ®Google Scholar
• Vitale S, Ellwein L, Cotch MF, et al. Prevalence of refractive error in the United States, 1999–2004. Arch Ophthalmol. 2008;126:1111–1119. doi:10.1001/archopht.126.8.1111.
   PubMedGoogle Scholar
• Katz J, Tielsch JM, Sommer A. Prevalence and risk factors for refractive errors in an adult inner city population. Invest Ophthalmol Vis Sci. 1997;38:334–340.
   PubMed Web of Science ®Google Scholar
• Williams KM, Bertelsen G, Cumberland P, et al. Increasing Prevalence of Myopia in Europe and the Impact of Education. Ophthalmology. 2015;122:1489–1497. doi:10.1016/j.ophtha.2015.03.018.
   PubMed Web of Science ®Google Scholar
• Wong TY, Foster PJ, Hee J, et al. Prevalence and risk factors for refractive errors in adult Chinese in Singapore. Invest Ophthalmol Vis Sci. 2000;41:2486–2494.
   PubMed Web of Science ®Google Scholar
• Pan CW, Wong TY, Lavanya R, et al. Prevalence and risk factors for refractive errors in Indians: the Singapore Indian Eye Study (SINDI). Invest Ophthalmol Vis Sci. 2011;52:3166–3173. doi:10.1167/iovs.10-6210.
   PubMed Web of Science ®Google Scholar
• Krishnaiah S, Srinivas M, Khanna RC, et al. Prevalence and risk factors for refractive errors in the South Indian adult population: the Andhra Pradesh Eye disease study. Clin Ophthalmol. 2009;3:17–27.
   PubMedGoogle Scholar
• Verhoeven VJ, Wong KT, Buitendijk GH, et al. Visual consequences of refractive errors in the general population. Ophthalmology. 2015;122:101–109. doi:10.1016/j.ophtha.2014.07.030.
   PubMed Web of Science ®Google Scholar
• Xu L, Wang Y, Li Y, et al. Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study. Ophthalmology. 2006;113:1134. doi:10.1016/j.ophtha.2006.04.029.
   PubMed Web of Science ®Google Scholar
• Iwase A, Araie M, Tomidokoro A, et al. Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study. Ophthalmology. 2006;113:1354–1362. doi:10.1016/j.ophtha.2006.04.022.
   PubMed Web of Science ®Google Scholar
• Van Newkirk MR. The Hong Kong vision study: a pilot assessment of visual impairment in adults. Trans Am Ophthalmol Soc. 1997;95:715–749.
   PubMedGoogle Scholar
• Tang Y, Wang X, Wang J, et al. Prevalence and Causes of Visual Impairment in a Chinese Adult Population: the Taizhou Eye Study. Ophthalmology. 2015;122:1480–1488. doi:10.1016/j.ophtha.2015.03.022.
   PubMed Web of Science ®Google Scholar
• Morgan IG, Ohno-Matsui K, Saw SM. Myopia. Lancet. 2012;379:1739–1748. doi:10.1016/S0140-6736(12)60272-4.
   PubMed Web of Science ®Google Scholar
• Cohen SY, Laroche A, Leguen Y, et al. Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996;103:1241–1244.
   PubMed Web of Science ®Google Scholar
• Daubs JG. Some geographic, environmental and nutritive concomitants of malignant myopia. Ophthalmic Physiol Opt. 1984;4:143–149.
   PubMed Web of Science ®Google Scholar
• Curtin BJ, Karlin DB. Axial length measurements and fundus changes of the myopic eye. I. The posterior fundus. Trans Am Ophthalmol Soc. 1970;68:312–334.
   PubMedGoogle Scholar
• Hayashi K, Ohno-Matsui K, Shimada N, et al. Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology. 2010;117:1595–1611. doi:10.1016/j.ophtha.2009.11.003.
   PubMed Web of Science ®Google Scholar
• Grossniklaus HE, Green WR. Pathologic findings in pathologic myopia. Retina. 1992;12:127–133.
   PubMed Web of Science ®Google Scholar
• Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121:682–92. doi:10.1016/j.ophtha.2013.10.023.
   PubMed Web of Science ®Google Scholar
• Ikuno Y, Ohno-Matsui K, Wong TY, et al. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: the MYRROR Study. Ophthalmology. 2015;122:1220–7. doi:10.1016/j.ophtha.2015.01.025.
   PubMed Web of Science ®Google Scholar
• Tufail A, Patel PJ, Sivaprasad S, et al. Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye (Lond). 2013;27:709–715. doi:10.1038/eye.2013.8.
   PubMed Web of Science ®Google Scholar
• Leveziel N, Caillaux V, Bastuji-Garin S, et al. Angiographic and optical coherence tomography characteristics of recent myopic choroidal neovascularization. Am J Ophthalmol. 2013;155:913–919. doi:10.1016/j.ajo.2012.11.021.
   PubMed Web of Science ®Google Scholar
• Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol. 2003;87:570–573.
   PubMed Web of Science ®Google Scholar
• Ikuno Y, Jo Y, Hamasaki T, et al. Ocular risk factors for choroidal neovascularization in pathologic myopia. Invest Ophthalmol Vis Sci. 2010;51:3721–3725. doi:10.1167/iovs.09-3493.
   PubMed Web of Science ®Google Scholar
• Wakabayashi T, Ikuno Y. Choroidal filling delay in choroidal neovascularisation due to pathological myopia. Br J Ophthalmol. 2010;94:611–615. doi:10.1136/bjo.2009.163535.
   PubMed Web of Science ®Google Scholar
• Leveziel N, Yu Y, Reynolds R, et al. Genetic factors for choroidal neovascularization associated with high myopia. Invest Ophthalmol Vis Sci. 2012;53:5004–5009. doi:10.1167/iovs.12-9538.
   PubMed Web of Science ®Google Scholar
• Miyake M, Yamashiro K, Nakanishi H, et al. Evaluation of pigment epithelium-derived factor and complement factor I polymorphisms as a cause of choroidal neovascularization in highly myopic eyes. Invest Ophthalmol Vis Sci. 2013;54:4208–4212. doi:10.1167/iovs.13-12280.
   PubMed Web of Science ®Google Scholar
• Avila MP, Weiter JJ, Jalkh AE, et al. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology. 1984;91:1573–1581.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology. 2003;110:1297–305. doi:10.1016/S0161-6420(03)00461-5.
   PubMed Web of Science ®Google Scholar
• Kojima A, Ohno-Matsui K, Teramukai S, et al. Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol. 2006;244:1474–1479. doi:10.1007/s00417-006-0324-4.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Ohno-Matsui K, Yoshida T, et al. Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2005;243:13–19. doi:10.1007/s00417-004-0960-5.
   PubMed Web of Science ®Google Scholar
• Ng DS, Kwok AK, Tong JM, et al. Factors influencing need for retreatment and long-term visual outcome after intravitreal bevacizumab for myopic choroidal neovascularization. Retina. 2015;35:2457–2468. doi:10.1097/IAE.0000000000000610.
   PubMed Web of Science ®Google Scholar
• Yang HS, Kim JG, Kim JT, et al. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab. Am J Ophthalmol. 2013;156:1201–1210. doi:10.1016/j.ajo.2013.08.002.
   PubMed Web of Science ®Google Scholar
• Wong TY, Ohno-Matsui K, Leveziel N, et al. Myopic choroidal neovascularisation: current concepts and update on clinical management. Br J Ophthalmol. 2015;99:289–296. doi:10.1136/bjophthalmol-2014-305131.
   PubMed Web of Science ®Google Scholar
• Chan WM, Ohji M, Lai TY, et al. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol. 2005;89:1522–1528. doi:10.1136/bjo.2005.074716.
   PubMed Web of Science ®Google Scholar
• Jalkh AE, Weiter JJ, Trempe CL, et al. Choroidal neovascularization in degenerative myopia: role of laser photocoagulation. Ophthalmic Surg. 1987;18:721–725.
   PubMedGoogle Scholar
• Virgili G, Menchini F. Laser photocoagulation for choroidal neovascularisation in pathologic myopia. Cochrane Database Syst Rev. 2005;4:CD004765.
   Google Scholar
• Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Ophthalmology. 2003;110:667–673.
   PubMed Web of Science ®Google Scholar
• Group ViPTS. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. Ophthalmology. 2001;108:841–852.
   PubMed Web of Science ®Google Scholar
• Adatia FA, Luong M, Munro M, et al. The other CNVM: a review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents. Surv Ophthalmol. 2015;60:204–215. doi:10.1016/j.survophthal.2014.10.002.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Ohno-Matsui K, Teramukai S, et al. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am J Ophthalmol. 2009;148:396–408. doi:10.1016/j.ajo.2009.03.026.
   PubMed Web of Science ®Google Scholar
• Ikuno Y, Nagai Y, Matsuda S, et al. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol. 2010;149:140–146. doi:10.1016/j.ajo.2009.08.008.
   PubMed Web of Science ®Google Scholar
• Parodi MB, Iacono P, Papayannis A, et al. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol. 2010;128:437–442. doi:10.1001/archophthalmol.2009.408.
   PubMed Web of Science ®Google Scholar
• Wang E, Chen Y. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina. 2013;33:1375–1392. doi:10.1097/IAE.0b013e31827d260a.
   PubMed Web of Science ®Google Scholar
• Parravano M, Ricci F, Oddone F, et al. Long-term functional and morphologic retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization. Retina. 2014;34:2053–2062. doi:10.1097/IAE.0000000000000201.
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno JM, Montero JA, Gomez-Ulla F. Photodynamic therapy may worsen the prognosis of highly myopic choroidal neovascularisation treated by intravitreal bevacizumab. Br J Ophthalmol. 2009;93:1693–1694. doi:10.1136/bjo.2008.147611.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431. doi:10.1056/NEJMoa054481.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855–859. doi:10.1016/j.ophtha.2007.01.017.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179–2182. doi:10.1016/j.ophtha.2007.09.012.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400. doi:10.1038/nrd1381.
   PubMed Web of Science ®Google Scholar
• Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008;92:667–668. doi:10.1136/bjo.2007.134874.
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–185. doi:10.1007/s10456-011-9249-6.
   PubMed Web of Science ®Google Scholar
• Gharbiya M, Giustolisi R, Allievi F, et al. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial. Am J Ophthalmol. 2010;149:458–464. doi:10.1016/j.ajo.2009.10.010.
   PubMed Web of Science ®Google Scholar
• Iacono P, Parodi MB, Papayannis A, et al. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina. 2012;32:1539–1546. doi:10.1097/IAE.0b013e31826956b7.
   PubMed Web of Science ®Google Scholar
• Pece A, Milani P, Monteleone C, et al. A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV. Graefes Arch Clin Exp Ophthalmol. 2015;253:1867–1872. doi:10.1007/s00417-014-2886-x.
   PubMed Web of Science ®Google Scholar
• Hashemi S, Faramarzi MA, Ghasemi Falavarjani K, et al. Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia. Expert Opin Biol Ther. 2014;14:1837–1848. doi:10.1517/14712598.2014.967210.
   PubMed Web of Science ®Google Scholar
• Wakabayashi T, Ikuno Y, Gomi F. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia. Retina. 2011;31:880–886. doi:10.1097/IAE.0b013e3181f2a293.
   PubMed Web of Science ®Google Scholar
• Cohen SY, Nghiem-Buffet S, Grenet T, et al. Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab. Jpn J Ophthalmol. 2015;59:36–42. doi:10.1007/s10384-014-0363-z.
   PubMed Web of Science ®Google Scholar
• Kung YH, Wu TT, Huang YH. One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization. Acta Ophthalmol. 2014;92:e615–20. doi:10.1111/aos.12457.
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno JM, Montero JA, Arias L, et al. Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization. Acta Ophthalmol. 2012;90:e82–3. doi:10.1111/j.1755-3768.2010.02070.x.
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno JM, Montero JA, Amat-Peral P. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses. Graefes Arch Clin Exp Ophthalmol. 2011;249:595–599. doi:10.1007/s00417-010-1599-z.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Ohno-Matsui K, Shimada N, et al. Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy. Graefes Arch Clin Exp Ophthalmol. 2009;247:609–618. doi:10.1007/s00417-008-1021-2.
   PubMed Web of Science ®Google Scholar
• Hefner L, Riese J, Gerding H. Three years follow-up results of ranibizumab treatment for choroidal neovascularization secondary to pathologic myopia. Klin Monbl Augenheilkd. 2013;230:401–404. doi:10.1055/s-0032-1328366.
   PubMed Web of Science ®Google Scholar
• Freitas-da-Costa P, Pinheiro-Costa J, Carvalho B, et al. Anti-VEGF therapy in myopic choroidal neovascularization: long-term results. Ophthalmologica. 2014;232:57–63. doi:10.1159/000360307.
   PubMed Web of Science ®Google Scholar
• Ladaique M, Dirani A, Ambresin A. Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab. Klin Monbl Augenheilkd. 2015;232:542–547. doi:10.1055/s-0035-1545817.
   PubMed Web of Science ®Google Scholar
• Farinha CL, Baltar AS, Nunes SG, et al. Progression of myopic maculopathy after treatment of choroidal neovascularization. Ophthalmologica. 2014;231:211–220. doi:10.1159/000357290.
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno JM, Montero JA, Araiz J, et al. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to pathologic myopia: Six Years Outcome. Retina. 2015;35:2450–2456. doi:10.1097/IAE.0000000000000632.
   PubMed Web of Science ®Google Scholar
• Oishi A, Yamashiro K, Tsujikawa A, et al. Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2013;251:1–7. doi:10.1007/s00417-012-2022-8.
   PubMed Web of Science ®Google Scholar
• Kang HM, Koh HJ. Ocular risk factors for recurrence of myopic choroidal neovascularization: long-term follow-up study. Retina. 2013;33:1613–1622. doi:10.1097/IAE.0b013e318285cc24.
   PubMed Web of Science ®Google Scholar
• Bruè C, Pazzaglia A, Mariotti C, et al. Aflibercept as primary treatment for myopic choroidal neovascularisation: a retrospective study. Eye (Lond). 2016;30:139–145. doi:10.1038/eye.2015.199.
   PubMed Web of Science ®Google Scholar
• Parodi MB, Iacono P, Sacconi R, et al. Fundus Autofluorescence Changes After Ranibizumab Treatment for Subfoveal Choroidal Neovascularization Secondary to Pathologic Myopia. Am J Ophthalmol. 2015;160:322–327. doi:10.1016/j.ajo.2015.04.030.
   PubMed Web of Science ®Google Scholar
• Ohno-Matsui K, Ito M, Tokoro T. Subretinal bleeding without choroidal neovascularization in pathologic myopia. A sign of new lacquer crack formation. Retina. 1996;16:196–202.
   PubMed Web of Science ®Google Scholar
• Gaucher D, Erginay A, Lecleire-Collet A, et al. Dome-shaped macula in eyes with myopic posterior staphyloma. Am J Ophthalmol. 2008;145:909–914. doi:10.1016/j.ajo.2008.01.012.
   PubMed Web of Science ®Google Scholar
• Mehdizadeh M, Nowroozzadeh MH. Dome-shaped macula in eyes with myopic posterior staphyloma. Am J Ophthalmol. 2008;146:478. doi:10.1016/j.ajo.2008.05.045.
   PubMed Web of Science ®Google Scholar
• Imamura Y, Iida T, Maruko I, et al. Enhanced depth imaging optical coherence tomography of the sclera in dome-shaped macula. Am J Ophthalmol. 2011;151:297–302. doi:10.1016/j.ajo.2010.08.014.
   PubMed Web of Science ®Google Scholar
• Errera MH, Michaelides M, Keane PA, et al. The extended clinical phenotype of dome-shaped macula. Graefes Arch Clin Exp Ophthalmol. 2014;252:499–508. doi:10.1007/s00417-013-2561-7.
   PubMed Web of Science ®Google Scholar
• Liang IC, Shimada N, Tanaka Y, et al. Comparison of Clinical Features in Highly Myopic Eyes with and without a Dome-Shaped Macula. Ophthalmology. 2015;122:1591–1600. doi:10.1016/j.ophtha.2015.04.012.
   PubMed Web of Science ®Google Scholar
• Ceklic L, Wolf-Schnurrbusch U, Gekkieva M, et al. Visual acuity outcome in RADIANCE study patients with dome-shaped macular features. Ophthalmology. 2014;121:2288–2289. doi:10.1016/j.ophtha.2014.06.012.
   PubMed Web of Science ®Google Scholar
• Watzke RC, Packer AJ, Folk JC, et al. Punctate inner choroidopathy. Am J Ophthalmol. 1984;98:572–584.
   PubMed Web of Science ®Google Scholar
• Channa R, Ibrahim M, Sepah Y, et al. Characterization of macular lesions in punctate inner choroidopathy with spectral domain optical coherence tomography. J Ophthalmic Inflamm Infect. 2012;2:113–120. doi:10.1007/s12348-011-0054-6.
   PubMedGoogle Scholar
• Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–1908. doi:10.1056/NEJMoa1102673.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–1203. doi:10.1056/NEJMoa1414264.
   PubMed Web of Science ®Google Scholar
• Introini U, Casalino G, Querques G, et al. Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization. Eye (Lond). 2012;26:976–982. doi:10.1038/eye.2012.75.
   PubMed Web of Science ®Google Scholar
• Battaglia Parodi M, Iacono P, Bandello F. Correspondence of leakage on fluorescein angiography and optical coherence tomography parameters in diagnosis and monitoring of myopic choroidal neovascularization treated with bevacizumab. Retina. 2016;36:104–109. doi:10.1097/IAE.0000000000000684.
   PubMed Web of Science ®Google Scholar
• Keane PA, Liakopoulos S, Chang KT, et al. Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis. Br J Ophthalmol. 2008;92:1081–1085. doi:10.1136/bjo.2008.138891.
   PubMed Web of Science ®Google Scholar
• Iacono P, Battaglia Parodi M, Papayannis A, et al. Fluorescein angiography and spectral-domain optical coherence tomography for monitoring anti-VEGF therapy in myopic choroidal neovascularization. Ophthalmic Res. 2014;52:25–31. doi:10.1159/000358331.
   PubMed Web of Science ®Google Scholar